½ÃÀ庸°í¼­
»óǰÄÚµå
1602791

¼¼°èÀÇ Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ÀûÀÀÁõº°, ¿ëµµº° - ¿¹Ãø(2025-2030³â)

Anti-Inflammatory Therapeutics Market by Drug Class (Anti-inflammatory Biologics, Corticosteroids, Non-steroidal Anti-inflammatory Drugs ), Indication, Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 199 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀåÀº 2023³â¿¡ 1,015¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 1,038¾ï 5,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 4.93%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 1,422¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå¿¡´Â °üÀý¿°, õ½Ä, ¿°Áõ¼º Àå Áúȯ µî ¸¹Àº Áúº´¿¡ °øÅëÀûÀÎ °æ·ÎÀÎ ¿°ÁõÀ» ¿ÏÈ­Çϱâ À§ÇÑ Ä¡·á°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¼ö¿äÀÇ ±ÞÁõÀº °í·ÉÈ­, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¿°Áõ¼º Áúȯ¿¡ ´ëÇÑ Á¶±â °³ÀÔÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀǽÄÀÇ °íÁ¶·Î ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. Ç׿°Áõ Ä¡·á´Â Çö´ë ÀÇ·á¿¡ ÇʼöÀûÀ̸ç ÀǾàǰ, »ý¹°Á¦Á¦, ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ÀÀ¿ëµÇ¸ç ÃÖÁ¾ »ç¿ëÀÚ´Â º´¿øÀ̳ª Ŭ¸®´Ð¿¡¼­ ¿¬±¸±â°ü±îÁö ´Ù¾çÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº ¹ÙÀÌ¿À Å×Å©³î·ÎÁöÀÇ Áøº¸, »õ·Î¿î Ä¡·á¹ýÀÇ Ã¤ÅÃ, ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¼¼°èÀÇ ÅõÀÚÀÇ Áõ°¡¿¡ ÀÇÇØ Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °³º°È­ ÀÇ·á¿Í Ç¥Àû ¿ä¹ýÀº, À¯È¿¼ºÀÇ Çâ»ó°ú ºÎÀÛ¿ëÀÇ °æ°¨À» ¾à¼ÓÇÏ´Â »õ·Î¿î ±âȸ¸¦ ±âÀçÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ ºÎ¹®Àº ÁÖ¿ä Áö¿ªÀÇ À¯¸®ÇÑ ±ÔÁ¦ Ʋ°ú ½Å¼ÓÇÑ ÀǾàǰ ½ÂÀÎ ÇÁ·Î¼¼½º¿¡ ÈûÀÔ¾î Çõ½Å°ú ¿¬±¸¸¦ À§ÇÑ ºñ¿ÁÇÑ Åä¾çÀ¸·Î Áö¼ÓµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¿¡µµ ºÒ±¸Çϰí, ½ÃÀåÀº ¿¬±¸ °³¹ß ºñ¿ëÀÇ ³ôÀÌ, ±ÔÁ¦ ¿ä°ÇÀÇ ¾ö°ÝÇÔ, ºÎÀÛ¿ëÀÇ °¡´É¼ºÀ̶ó°í ÇÏ´Â °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ¾î, À̰ÍÀÌ ½ÃÀå Âü°¡³ª ½ÃÀå °³Ã´¿¡ ¹æÇذ¡ µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Á¦³×¸¯ ÀǾàǰÀ̳ª ´ëü ÀÇ·á¿ÍÀÇ °æÇÕÀÌ ½ÃÀå È®´ëÀÇ À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ »ç¾÷ ¼ºÀåÀ» À§Çؼ­´Â ±â¾÷Àº AI¸¦ Ȱ¿ëÇÑ ½Å¾àÀ̳ª ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ß°ú °°Àº Çõ½ÅÀûÀÎ Á¢±Ù¿¡ ÁÖ·ÂÇØ¾ß ÇÕ´Ï´Ù. °Ô´Ù°¡ Àü·«Àû Á¦ÈÞÀÇ Çü¼ºÀ̳ª ½ÅÈï±¹¿¡ ´ëÇÑ ÅõÀÚ´Â °æÀï»óÀÇ ¿ìÀ§¼ºÀ» °¡Á®¿Ã °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ¼ºÁúÀº ¿ªµ¿ÀûÀ̸ç, °úÇÐÀÇ Áøº¸³ª ȯÀÚ Áß½ÉÀÇ Á¢±Ù¹ýÀÇ Áõ°¡¿¡ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ±â¾÷Àº ±â¹ÎÇÏ°Ô ÇൿÇÏ°í ±ÔÁ¦ º¯È­¿Í ±â¼ú Áøº¸¸¦ ÁÖÀÇ ±í°Ô ¸ð´ÏÅ͸µÇÏ¿© ÀáÀçÀûÀÎ ½ÃÀå º¯È­¸¦ Æ÷ÂøÇØ¾ß ÇÕ´Ï´Ù. ÀüÀÎÀûÀÌ°í ¿¡ºñ´ø½ºº° Ä¡·áÀÇ Á߿伺À» ÀνÄÇÏ°í ¼¼±×¸ÕÆ® Ⱦ´ÜÀûÀÎ Çù¾÷À» ÃËÁøÇÏ´Â °ÍÀÌ Ç׿°Áõ Ä¡·á ½ÃÀåÀÇ ÇâÈÄ ¼ºÀå ±âȸ¸¦ Æ÷ÂøÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ (2023³â) 1,015¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 1,038¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 1,422¾ï 1,000¸¸ ´Þ·¯
CAGR(%) 4.93%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç °áÁ¤, »õ·Î¿î ºñÁî´Ï½º Âù½ºÀÇ È¹µæÀ» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Æ÷°ýÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖ´Â µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇØ º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼º ÁúȯÀÇ ¼¼°èÀÇ ´Ù¹ß
    • ¿°Áõ¼º ÁúȯÀÇ Ä¡·á¿¡ À־ÀÇ »ý¹° Á¦Á¦ÀÇ ÀÌ¿ë °¡´É¼º Áõ°¡
    • ¿°Áõ¼º Ä¡·áÀÇ ÀÎÁöµµ È®´ë¸¦ ÇâÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºêÀÇ °íÁ¶
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ç׿°Áõ Ä¡·áÁ¦¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • Ç׿°Áõ Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ ¿¬±¸ °³¹ßÀÇ È°¼ºÈ­
    • Ç׿°Áõ Ä¡·áÁ¦ ½ÂÀÎ °úÁ¤ÀÇ »ó½Â
  • ½ÃÀåÀÇ °úÁ¦
    • Ç׿°Áõ Ä¡·áÁ¦¿¡ µû¸¥ ƯÁ¤ ºÎÀÛ¿ë

Porter's Five Forces : Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ã±â À§ÇÑ ¸íÈ®ÇÑ ±â¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ÆÇµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡¿¡ ´ëóÇϸç, ÀáÀçÀûÀÎ °úÁ¦¸¦ ȸÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡, °æÁ¦, »çȸ, ±â¼ú, ¹ý ¹× ȯ°æ ¿äÀÎ ºÐ¼® ´Â ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÕÀ¸·Î ¿¹»óÇÑ Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µîÀÇ ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÔÀ¸·Î½á °æÀï»óÀÇ Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®¿¡ ÀÇÇØ ½ÃÀåÀÇ ÁýÁß, ´ÜÆíÈ­, ÅëÇÕÀÇ µ¿ÇâÀÌ ¹àÇôÁ® º¥´õ´Â °æÀïÀÌ °ÝÈ­µÇ´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ½Ç½ÃÇϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ßÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ ´Ù·ç´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®¿¡¼­ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ¼³¸íÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡µµ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À² ¹× °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
      • ¿°Áõ¼º ÁúȯÀÇ Ä¡·á¿¡¼­ »ý¹° Á¦Á¦ÀÇ ÀÌ¿ë °¡´É¼ºÀÇ Áõ´ë
      • ¿°ÁõÄ¡·áÀÇ ÀÎÁöµµ¸¦ ³ôÀÌ´Â Á¤ºÎÀÇ ´ëó°¡ È®´ë
    • ¾ïÁ¦¿äÀÎ
      • Ç׿°Áõ Ä¡·áÁ¦¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë
    • ±âȸ
      • Ç׿°Áõ Ä¡·áÁ¦¸¦ °³¹ßÇϱâ À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿ È®´ë
      • Ç׿°Áõ Ä¡·áÁ¦ ½ÂÀÎ ÇÁ·Î¼¼½º Áõ°¡
    • °úÁ¦
      • Ç׿°Áõ Ä¡·áÁ¦¿Í °ü·ÃµÈ ƯÁ¤ ºÎÀÛ¿ë
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

  • ¼­¹®
  • Ç׿°Áõ »ý¹° Á¦Á¦
  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAID)

Á¦7Àå Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå : ÀûÀÀÁõº°

  • ¼­¹®
  • Ç׿°Áõ¼º ÀåÁúȯ
  • °üÀý¿°
  • ´Ù¹ß¼º °æÈ­Áõ
  • °Ç¼±
  • È£Èí±â Áúȯ

Á¦8Àå Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°

  • ¼­¹®
  • ÀÚ°¡¸é¿ª
  • ¿°Áõ¼º Áúȯ
  • È£Èí±â Áúȯ

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå

  • ¼­¹®
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå

  • ¼­¹®
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç׿°Áõ Ä¡·áÁ¦ ½ÃÀå

  • ¼­¹®
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbvie, Inc.
  • Algen Healthcare Ltd.
  • Allegiant Health
  • Alvogen
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Arcutis BIoTherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Clearsynth Labs Limited
  • Genentech, Inc. by Roche Group
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kymera Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Pharbest Pharmaceuticals, Inc.
  • Sanofi Group
  • Spectrum Chemical Mfg. Corp.
  • Sun Pharmaceutical Industries Ltd.
  • Teikoku Seiyaku Co., Ltd.
AJY 24.12.13

The Anti-Inflammatory Therapeutics Market was valued at USD 101.53 billion in 2023, expected to reach USD 103.85 billion in 2024, and is projected to grow at a CAGR of 4.93%, to USD 142.21 billion by 2030.

The anti-inflammatory therapeutics market encompasses treatments designed to alleviate inflammation, a common pathway in numerous diseases, including arthritis, asthma, and inflammatory bowel diseases. The burgeoning demand is fueled by an aging population, increasing prevalence of chronic diseases, and heightened awareness of the benefits of early intervention in inflammatory conditions. Anti-inflammatory therapeutics are essential in modern medicine, offering applications in pharmaceuticals, biologics, and biosimilars, with end-users ranging from hospitals and clinics to research institutes. Growth in this market is significantly influenced by advancements in biotechnology, the introduction of novel therapeutic methods, and the increasing investment in healthcare infrastructure globally. Personalized medicine and targeted therapies provide an emerging opportunity, promising enhanced efficacy and reduced side effects. The biopharmaceutical sector, supported by favorable regulatory frameworks and expedited drug approval processes in key regions, remains a fertile ground for innovation and research. Despite these opportunities, the market faces challenges such as high R&D costs, strict regulatory requirements, and the potential for adverse drug reactions, which can impede market entry and development. Furthermore, competition from generic drugs and alternative medicine poses a threat to market expansion. For sustainable business growth, companies should focus on innovative approaches like AI-driven drug discovery and the development of biosimilars. Additionally, forming strategic alliances and investing in emerging economies could offer competitive advantages. The nature of the market is dynamic, fueled by scientific advancements and increasing patient-centric approaches. Therefore, businesses should be agile, closely monitoring regulatory changes and technological advancements to seize potential market shifts. Recognizing the importance of holistic, evidence-based treatments, and fostering cross-disciplinary collaborations will be crucial for capturing future growth opportunities in the anti-inflammatory therapeutics market.

KEY MARKET STATISTICS
Base Year [2023] USD 101.53 billion
Estimated Year [2024] USD 103.85 billion
Forecast Year [2030] USD 142.21 billion
CAGR (%) 4.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Inflammatory Therapeutics Market

The Anti-Inflammatory Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of chronic disorders globally
    • Rising availability of biologic drugs for the treatment of inflammatory conditions
    • Growing government initiatives to expand the awareness of inflammatory therapeutics
  • Market Restraints
    • High cost associated with anti-inflammatory therapeutics
  • Market Opportunities
    • Growing research & development activities to develop anti-inflammatory therapeutics
    • Rising approval process for anti-inflammatory therapeutics
  • Market Challenges
    • Certain side effects associated with anti-inflammatory therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Inflammatory Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Inflammatory Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Inflammatory Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Inflammatory Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Inflammatory Therapeutics Market

A detailed market share analysis in the Anti-Inflammatory Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Inflammatory Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Inflammatory Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Inflammatory Therapeutics Market

A strategic analysis of the Anti-Inflammatory Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Inflammatory Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Algen Healthcare Ltd., Allegiant Health, Alvogen, Amgen Inc., Amneal Pharmaceuticals LLC, Arcutis Biotherapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Clearsynth Labs Limited, Genentech, Inc. by Roche Group, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kymera Therapeutics, Novartis AG, Pfizer Inc., Pharbest Pharmaceuticals, Inc., Sanofi Group, Spectrum Chemical Mfg. Corp., Sun Pharmaceutical Industries Ltd., and Teikoku Seiyaku Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Inflammatory Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-inflammatory Biologics, Corticosteroids, and Non-steroidal Anti-inflammatory Drugs (NSAIDs).
  • Based on Indication, market is studied across Anti-inflammatory Bowel Disease, Arthritis, Multiple Sclerosis, Psoriasis, and Respiratory Disease.
  • Based on Application, market is studied across Autoimmune, Inflammatory Diseases, and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic disorders globally
      • 5.1.1.2. Rising availability of biologic drugs for the treatment of inflammatory conditions
      • 5.1.1.3. Growing government initiatives to expand the awareness of inflammatory therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with anti-inflammatory therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research & development activities to develop anti-inflammatory therapeutics
      • 5.1.3.2. Rising approval process for anti-inflammatory therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Certain side effects associated with anti-inflammatory therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Inflammatory Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-inflammatory Biologics
  • 6.3. Corticosteroids
  • 6.4. Non-steroidal Anti-inflammatory Drugs (NSAIDs)

7. Anti-Inflammatory Therapeutics Market, by Indication

  • 7.1. Introduction
  • 7.2. Anti-inflammatory Bowel Disease
  • 7.3. Arthritis
  • 7.4. Multiple Sclerosis
  • 7.5. Psoriasis
  • 7.6. Respiratory Disease

8. Anti-Inflammatory Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune
  • 8.3. Inflammatory Diseases
  • 8.4. Respiratory Diseases

9. Americas Anti-Inflammatory Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-Inflammatory Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-Inflammatory Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Algen Healthcare Ltd.
  • 3. Allegiant Health
  • 4. Alvogen
  • 5. Amgen Inc.
  • 6. Amneal Pharmaceuticals LLC
  • 7. Arcutis Biotherapeutics, Inc.
  • 8. Astellas Pharma Inc.
  • 9. AstraZeneca PLC
  • 10. Bayer AG
  • 11. Bristol-Myers Squibb Company
  • 12. Clearsynth Labs Limited
  • 13. Genentech, Inc. by Roche Group
  • 14. GlaxoSmithKline PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Kymera Therapeutics
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Pharbest Pharmaceuticals, Inc.
  • 20. Sanofi Group
  • 21. Spectrum Chemical Mfg. Corp.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teikoku Seiyaku Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦